CRDF: Phase II response and durability signals underpin a planned pan-RAS colorectal cancer phase III trial
Less than 1 min read
Onvansertib plus FOLFOXIRI/bev showed 70%+ ORR vs 42% in phase II RAS-mutated colorectal cancer, with median PFS unreached in the treatment arm. A phase III trial is planned for Q1 2027, pending funding.
Based on Cardiff Oncology, Inc. [CRDF] UBS Global Biopharma Conference 2026 Audio Transcript — Nov. 16 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr